The Experts below are selected from a list of 1956 Experts worldwide ranked by ideXlab platform
George B Bartley - One of the best experts on this subject based on the ideXlab platform.
-
treatment options and future prospects for the management of Eyelid malignancies an evidence based update
Ophthalmology, 2001Co-Authors: Briggs E Cook, George B BartleyAbstract:Abstract Purpose To provide evidence-based clinical recommendations for treatment options and future prospects for the management of common malignant Eyelid Tumors, including global ratings for the strength of published evidence supporting them. Clinical relevance Approximately 5% to 10% of all skin cancers occur in the Eyelid. Incidence studies indicate that basal cell carcinoma is the most frequent malignant Eyelid Tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Many therapeutic methods have been suggested to combat the morbidity and mortality associated with these lesions. Literature reviewed A MEDLINE and PubMed literature search (1966–1999) was conducted for English language abstracts and appropriate (selected) full-text references retrieved regarding treatment of malignant Eyelid Tumors. These sources then were used to prepare recommendations for patient care. Each recommendation was rated according to: (1) its importance in the care process and (2) the strength of evidence supporting the given recommendation. Results All recommendations were rated as level A (very important to patient-care outcome). For basal cell carcinoma, squamous cell carcinoma, and sebaceous gland carcinoma, the published evidence supporting two recommendations (Mohs' micrographic surgery or excision with frozen-section control) were graded as I (providing strong evidence in support of a recommendation). For sebaceous gland carcinoma, the recommendations also included conjunctival map biopsies. The published evidence supporting all other recommendations for these three Eyelid Tumors were graded II (substantial evidence in support of a recommendation), primarily because of the small numbers of patients in each clinical study. For malignant melanoma, the recommendation for therapy (i.e., excision with variable margins depending on Tumor thickness) was based on published papers individually variably rated as I, II, and III, reflecting ongoing debate as to the best method of therapy. Conclusions Published reports regarding the treatment of malignant Eyelid Tumors include a myriad of treatment options. The strongest evidence favors complete surgical removal using histologic controls for verifying Tumor-free margins of excision.
-
epidemiologic characteristics and clinical course of patients with malignant Eyelid Tumors in an incidence cohort in olmsted county minnesota
Ophthalmology, 1999Co-Authors: Briggs E Cook, George B BartleyAbstract:Abstract Objective To determine the epidemiologic and clinical characteristics of patients with malignant Eyelid Tumors in an incidence cohort. Design Cohort series. Participants A computerized retrieval system was used to identify all patients residing in Olmsted County, Minnesota, who had a newly diagnosed malignant Eyelid Tumor during the 15-year interval from 1976 through 1990. The patients' medical records were reviewed for demographic and clinical data. Intervention Surgical excision with frozen-section histopathologic analysis, Mohs' micrographic excision, and electrodesiccation and curettage were the primary methods of treatment. Main outcome measures Survivorship free of Tumor. Results The incidence cohort included 174 patients who each had 1 Tumor; men and women were equally affected, and all patients were white. Tumors developed most commonly on the lower Eyelid ( n = 85; 48.9%) and in the medial canthal region ( n = 48; 27.6%) but involved the right and left sides with equal frequency. Of the 174 Tumors, 158 were basal cell carcinomas (90.8%), 15 were squamous cell carcinomas (8.6%), and 1 (0.6%) was a malignant melanoma. The age- and gender-adjusted incidence rates for basal cell carcinoma, squamous cell carcinoma, and malignant melanoma were 14.35, 1.37, and 0.08 per 100,000 individuals per year, respectively. No cases of sebaceous gland carcinoma were identified. The 5- and 10-year recurrence rates for all Tumors on the Eyelid were 2% and 3%, respectively. The probability of an unrelated malignancy developing elsewhere in the body was approximately 9% at 5 years and 15% at 10 years. Conclusions Basal cell carcinoma is the most common malignant Eyelid Tumor in whites. The lower Eyelid and medial canthus are the most frequent sites of origin. Men and women are equally affected. Recurrence after surgical excision is uncommon.
Roberto Lorens Marback - One of the best experts on this subject based on the ideXlab platform.
-
estudo clinico patologico do pilomatrixoma palpebral experiencia no hospital universitario prof edgard santos
Arquivos Brasileiros De Oftalmologia, 2007Co-Authors: Eduardo Ferrari Marback, Camila Correa Cardoso, Livia Maria Nossa Moitinho, Roberto Lorens MarbackAbstract:PURPOSE: To report the experience with Eyelid pilomatrixoma during 30 years in a university hospital. METHODS: A review of the Ophthalmic Pathology Laboratory at the "Hospital Universitario Prof. Edgard Santos", was conducted to identify Eyelid Tumor cases from 1974 to 2004. After identification of pilomatrixoma cases, a chart review retrieved data regarding gender, age, duration of symptoms, gross aspect, anatomic localization and clinical diagnosis. The hematoxilin and eosin stained sections were reviewed. RESULTS: Of a total of 621 Eyelid Tumors, four (0.64%) were pilomatrixomas. Three patients were male. The mean age at diagnosis was 25 years (from 8 to 54). Mean duration of symptoms was 5 months (from 2 to 12). In three cases the lesion was located in the inferior lid. Only one patient had a correct clinical diagnosis. Two cases exhibited a pseudo-capsule on histology. The case with 12 months of history was composed mainly of shadow cells. Foreign body reaction was seen in all cases, calcification in only one. CONCLUSION: This is a very rare benign Tumor of young patients. Due to its rarity and variable clinical presentation, clinical misdiagnosis is common.
-
Estudo clínico-patológico do pilomatrixoma palpebral: experiência no hospital universitário Prof. Edgard Santos Clinicopathologic study of Eyelid pilomatrixoma: the experience of the "Hospital Universitário Prof. Edgard Santos"
Conselho Brasileiro de Oftalmologia, 2007Co-Authors: Eduardo Ferrari Marback, Livia Maria Nossa Moitinho, Camila Cardoso, Roberto Lorens MarbackAbstract:OBJETIVO: Relatar a experiência com pilomatrixoma palpebral no Hospital Universitário Profº. Edgard Santos, em período de 30 anos. MÉTODOS: Revisão no Registro do Laboratório de Patologia Ocular, de todos os casos de Tumores palpebrais no período de 1974 a 2004. Após a identificação dos casos de pilomatrixoma, foram coletados dados referentes a gênero, idade, tempo de sintomatologia, aspecto, localização e suspeita diagnóstica inicial. As lâminas coradas pela hematoxilina e eosina foram revisadas. RESULTADOS: Dentre os 621 casos de Tumores palpebrais, quatro eram de pilomatrixoma (0,64%). Três pacientes eram do sexo masculino. A idade média foi de 25 anos, variando de 8 a 54. O tempo de sintomatologia médio foi de cinco meses, variando de 2 a 12. Em três casos a lesão localizava-se na pálpebra inferior. Em apenas um caso o diagnóstico clínico foi correto. Ao exame anatomopatológico, dois casos apresentavam pseudocápsula. O caso cuja sintomatologia foi mais prolongada exibia predominância de células do tipo fantasma. Reação tipo corpo estranho foi vista em todos os casos, calcificação em apenas um. CONCLUSÕES: Trata-se de Tumor benigno bastante raro, acometendo principalmente jovens. Devido a sua raridade e pleomorfismo à apresentação, dificilmente o diagnóstico clínico é correto.PURPOSE: To report the experience with Eyelid pilomatrixoma during 30 years in a university hospital. METHODS: A review of the Ophthalmic Pathology Laboratory at the "Hospital Universitario Prof. Edgard Santos", was conducted to identify Eyelid Tumor cases from 1974 to 2004. After identification of pilomatrixoma cases, a chart review retrieved data regarding gender, age, duration of symptoms, gross aspect, anatomic localization and clinical diagnosis. The hematoxilin and eosin stained sections were reviewed. RESULTS: Of a total of 621 Eyelid Tumors, four (0.64%) were pilomatrixomas. Three patients were male. The mean age at diagnosis was 25 years (from 8 to 54). Mean duration of symptoms was 5 months (from 2 to 12). In three cases the lesion was located in the inferior lid. Only one patient had a correct clinical diagnosis. Two cases exhibited a pseudo-capsule on histology. The case with 12 months of history was composed mainly of shadow cells. Foreign body reaction was seen in all cases, calcification in only one. CONCLUSION: This is a very rare benign Tumor of young patients. Due to its rarity and variable clinical presentation, clinical misdiagnosis is common
Briggs E Cook - One of the best experts on this subject based on the ideXlab platform.
-
treatment options and future prospects for the management of Eyelid malignancies an evidence based update
Ophthalmology, 2001Co-Authors: Briggs E Cook, George B BartleyAbstract:Abstract Purpose To provide evidence-based clinical recommendations for treatment options and future prospects for the management of common malignant Eyelid Tumors, including global ratings for the strength of published evidence supporting them. Clinical relevance Approximately 5% to 10% of all skin cancers occur in the Eyelid. Incidence studies indicate that basal cell carcinoma is the most frequent malignant Eyelid Tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Many therapeutic methods have been suggested to combat the morbidity and mortality associated with these lesions. Literature reviewed A MEDLINE and PubMed literature search (1966–1999) was conducted for English language abstracts and appropriate (selected) full-text references retrieved regarding treatment of malignant Eyelid Tumors. These sources then were used to prepare recommendations for patient care. Each recommendation was rated according to: (1) its importance in the care process and (2) the strength of evidence supporting the given recommendation. Results All recommendations were rated as level A (very important to patient-care outcome). For basal cell carcinoma, squamous cell carcinoma, and sebaceous gland carcinoma, the published evidence supporting two recommendations (Mohs' micrographic surgery or excision with frozen-section control) were graded as I (providing strong evidence in support of a recommendation). For sebaceous gland carcinoma, the recommendations also included conjunctival map biopsies. The published evidence supporting all other recommendations for these three Eyelid Tumors were graded II (substantial evidence in support of a recommendation), primarily because of the small numbers of patients in each clinical study. For malignant melanoma, the recommendation for therapy (i.e., excision with variable margins depending on Tumor thickness) was based on published papers individually variably rated as I, II, and III, reflecting ongoing debate as to the best method of therapy. Conclusions Published reports regarding the treatment of malignant Eyelid Tumors include a myriad of treatment options. The strongest evidence favors complete surgical removal using histologic controls for verifying Tumor-free margins of excision.
-
epidemiologic characteristics and clinical course of patients with malignant Eyelid Tumors in an incidence cohort in olmsted county minnesota
Ophthalmology, 1999Co-Authors: Briggs E Cook, George B BartleyAbstract:Abstract Objective To determine the epidemiologic and clinical characteristics of patients with malignant Eyelid Tumors in an incidence cohort. Design Cohort series. Participants A computerized retrieval system was used to identify all patients residing in Olmsted County, Minnesota, who had a newly diagnosed malignant Eyelid Tumor during the 15-year interval from 1976 through 1990. The patients' medical records were reviewed for demographic and clinical data. Intervention Surgical excision with frozen-section histopathologic analysis, Mohs' micrographic excision, and electrodesiccation and curettage were the primary methods of treatment. Main outcome measures Survivorship free of Tumor. Results The incidence cohort included 174 patients who each had 1 Tumor; men and women were equally affected, and all patients were white. Tumors developed most commonly on the lower Eyelid ( n = 85; 48.9%) and in the medial canthal region ( n = 48; 27.6%) but involved the right and left sides with equal frequency. Of the 174 Tumors, 158 were basal cell carcinomas (90.8%), 15 were squamous cell carcinomas (8.6%), and 1 (0.6%) was a malignant melanoma. The age- and gender-adjusted incidence rates for basal cell carcinoma, squamous cell carcinoma, and malignant melanoma were 14.35, 1.37, and 0.08 per 100,000 individuals per year, respectively. No cases of sebaceous gland carcinoma were identified. The 5- and 10-year recurrence rates for all Tumors on the Eyelid were 2% and 3%, respectively. The probability of an unrelated malignancy developing elsewhere in the body was approximately 9% at 5 years and 15% at 10 years. Conclusions Basal cell carcinoma is the most common malignant Eyelid Tumor in whites. The lower Eyelid and medial canthus are the most frequent sites of origin. Men and women are equally affected. Recurrence after surgical excision is uncommon.
Eduardo Ferrari Marback - One of the best experts on this subject based on the ideXlab platform.
-
estudo clinico patologico do pilomatrixoma palpebral experiencia no hospital universitario prof edgard santos
Arquivos Brasileiros De Oftalmologia, 2007Co-Authors: Eduardo Ferrari Marback, Camila Correa Cardoso, Livia Maria Nossa Moitinho, Roberto Lorens MarbackAbstract:PURPOSE: To report the experience with Eyelid pilomatrixoma during 30 years in a university hospital. METHODS: A review of the Ophthalmic Pathology Laboratory at the "Hospital Universitario Prof. Edgard Santos", was conducted to identify Eyelid Tumor cases from 1974 to 2004. After identification of pilomatrixoma cases, a chart review retrieved data regarding gender, age, duration of symptoms, gross aspect, anatomic localization and clinical diagnosis. The hematoxilin and eosin stained sections were reviewed. RESULTS: Of a total of 621 Eyelid Tumors, four (0.64%) were pilomatrixomas. Three patients were male. The mean age at diagnosis was 25 years (from 8 to 54). Mean duration of symptoms was 5 months (from 2 to 12). In three cases the lesion was located in the inferior lid. Only one patient had a correct clinical diagnosis. Two cases exhibited a pseudo-capsule on histology. The case with 12 months of history was composed mainly of shadow cells. Foreign body reaction was seen in all cases, calcification in only one. CONCLUSION: This is a very rare benign Tumor of young patients. Due to its rarity and variable clinical presentation, clinical misdiagnosis is common.
-
Estudo clínico-patológico do pilomatrixoma palpebral: experiência no hospital universitário Prof. Edgard Santos Clinicopathologic study of Eyelid pilomatrixoma: the experience of the "Hospital Universitário Prof. Edgard Santos"
Conselho Brasileiro de Oftalmologia, 2007Co-Authors: Eduardo Ferrari Marback, Livia Maria Nossa Moitinho, Camila Cardoso, Roberto Lorens MarbackAbstract:OBJETIVO: Relatar a experiência com pilomatrixoma palpebral no Hospital Universitário Profº. Edgard Santos, em período de 30 anos. MÉTODOS: Revisão no Registro do Laboratório de Patologia Ocular, de todos os casos de Tumores palpebrais no período de 1974 a 2004. Após a identificação dos casos de pilomatrixoma, foram coletados dados referentes a gênero, idade, tempo de sintomatologia, aspecto, localização e suspeita diagnóstica inicial. As lâminas coradas pela hematoxilina e eosina foram revisadas. RESULTADOS: Dentre os 621 casos de Tumores palpebrais, quatro eram de pilomatrixoma (0,64%). Três pacientes eram do sexo masculino. A idade média foi de 25 anos, variando de 8 a 54. O tempo de sintomatologia médio foi de cinco meses, variando de 2 a 12. Em três casos a lesão localizava-se na pálpebra inferior. Em apenas um caso o diagnóstico clínico foi correto. Ao exame anatomopatológico, dois casos apresentavam pseudocápsula. O caso cuja sintomatologia foi mais prolongada exibia predominância de células do tipo fantasma. Reação tipo corpo estranho foi vista em todos os casos, calcificação em apenas um. CONCLUSÕES: Trata-se de Tumor benigno bastante raro, acometendo principalmente jovens. Devido a sua raridade e pleomorfismo à apresentação, dificilmente o diagnóstico clínico é correto.PURPOSE: To report the experience with Eyelid pilomatrixoma during 30 years in a university hospital. METHODS: A review of the Ophthalmic Pathology Laboratory at the "Hospital Universitario Prof. Edgard Santos", was conducted to identify Eyelid Tumor cases from 1974 to 2004. After identification of pilomatrixoma cases, a chart review retrieved data regarding gender, age, duration of symptoms, gross aspect, anatomic localization and clinical diagnosis. The hematoxilin and eosin stained sections were reviewed. RESULTS: Of a total of 621 Eyelid Tumors, four (0.64%) were pilomatrixomas. Three patients were male. The mean age at diagnosis was 25 years (from 8 to 54). Mean duration of symptoms was 5 months (from 2 to 12). In three cases the lesion was located in the inferior lid. Only one patient had a correct clinical diagnosis. Two cases exhibited a pseudo-capsule on histology. The case with 12 months of history was composed mainly of shadow cells. Foreign body reaction was seen in all cases, calcification in only one. CONCLUSION: This is a very rare benign Tumor of young patients. Due to its rarity and variable clinical presentation, clinical misdiagnosis is common
Sinan Nazlım - One of the best experts on this subject based on the ideXlab platform.
-
Histopathology results of primary Eyelid Tumors
Dicle University Medical School, 2015Co-Authors: Ali Kurt, Sait Nafiz Mutlu, Halil İbrahim Yener, Nurettin Bayram, Sinan NazlımAbstract:Objective: To evaluate the histopathological results of cases who presented with an Eyelid mass and underwent mass excision. Methods: The histopathological results of 107 cases, who underwent Eyelid mass excision between May 2011 and March 2014 were retrospectively analyzed. Age and sex, mass localization, operative technique, and histopathological results were recorded. Results: Of 107 subjects included in the study, 61 were male and 46 were female, with a mean age of 49.44±19.81 years. The distribution of benign Eyelid Tumors were as follows: 37 (37.8%) squamous papillomas, 19 (19.4%) intradermal nevus, 9 (9.2%) seborrheic keratosis, 7 (7.1%) epidermal inclusion cyst, 6 (6.1%) inflammatory lesions, 5 (5.1%) suderiferous cysts, 5 (5.1%) capillary hemangiomas, 3 (3.1%) xanthelasma, 3 (3.1%) fibromas, 1 (1.0%) moll gland cyst, 1 (1.0%) chondroid syringoma, 1 (1.0%) dermoid cyst, and 1 (1.0%) actinic keratosis. Malignant Eyelid Tumors included 8 (88.9%) cases of basal cell carcinomas and 1 (11.1%) squamous cell carcinoma. Conclusion: In this study squamous papilloma was the most common benign Eyelid Tumor followed by intradermal nevus. Basal cell carcinoma was the most common malignant Eyelid Tumor followed by squamous cell carcinoma
-
Histopathology results of primary Eyelid Tumors
2015Co-Authors: Ali Kurt, Sait Nafiz Mutlu, Halil İbrahim Yener, Nurettin Bayram, Sinan NazlımAbstract:Amaç: Göz kapağında kitle nedeniyle başvuran ve kitle eksizyonu yapılan olguların histopatolojik sonuçlarını değerlendirmek. Yöntemler: Mayıs 2011 ile Mart 2014 tarihleri arasında göz kapağı kitlesi eksizyonu yapılan 107 olgunun histopatolojik sonuçları retrospektif olarak değerlendirildi. Vakaların yaşı ve cinsiyeti, kitlenin lokalizasyonu, ameliyat tekniği ve histopatolojik tanıları kaydedildi. Bulgular: Çalışmaya dahil edilen 107 hastanın 61’i erkek, 46’sı kadın olup yaş ortalaması 49,44±19,81 yıl idi. İyi huylu göz kapağı tümörlerinin histopatolojik sonuçlarına göre dağılımı skuamöz papillom 37 olgu (%37,8), intradermal nevüs 19 olgu (%19,4), seboreik keratoz 9 olgu (%9,2), epidermal inklüzyon kisti 7 olgu (%7,1), inflamatuar lezyon 6 olgu (%6,1), suderiferöz kist 5 olgu (%5,1), kapiller hemanjiom 5 olgu (%5,1), ksantelezma 3 olgu (%3,1), fibrom 3 olgu (%3,1), moll gland kisti 1 olgu (%1,0), kondroid syringoma 1 olgu (%1,0), dermoid kist 1 olgu (%1,0), aktinik keratoz 1 olgu (%1,0) idi. Kötü huylu göz kapağı tümörlerinin histopatolojik sonuçlarına göre dağılımı bazal hücreli karsinom 8 olgu (%88,9), yassı hücreli karsinom 1 olgu (%11,1) idi. Sonuç: Çalışmamızda skuamöz papillom en sık görülen iyi huylu kapak tümörüdür ve bunu ikinci sırada intradermal nevüs izlemektedir. Kötü huylu kapak tümörlerinde en sık bazal hücreli karsinom gözlenmektedir, bunu ikinci sırada yassı hücreli karsinom izlemektedir.Objective: To evaluate the histopathological results of cases who presented with an Eyelid mass and underwent mass excision. Methods: The histopathological results of 107 cases, who underwent Eyelid mass excision between May 2011 and March 2014 were retrospectively analyzed. Age and sex, mass localization, operative technique, and histopathological results were recorded. Results: Of 107 subjects included in the study, 61 were male and 46 were female, with a mean age of 49.44±19.81 years. The distribution of benign Eyelid Tumors were as follows: 37 (37.8%) squamous papillomas, 19 (19.4%) intradermal nevus, 9 (9.2%) seborrheic keratosis, 7 (7.1%) epidermal inclusion cyst, 6 (6.1%) infammatory lesions, 5 (5.1%) suderiferous cysts, 5 (5.1%) capillary hemangiomas, 3 (3.1%) xanthelasma, 3 (3.1%) fbromas, 1 (1.0%) moll gland cyst, 1 (1.0%) chondroid syringoma, 1 (1.0%) dermoid cyst, and 1 (1.0%) actinic keratosis. Malignant Eyelid Tumors included 8 (88.9%) cases of basal cell carcinomas and 1 (11.1%) squamous cell carcinoma. Conclusion: In this study squamous papilloma was the most common benign Eyelid Tumor followed by intradermal nevus. Basal cell carcinoma was the most common malignant Eyelid Tumor followed by squamous cell carcinoma
